ClinicaliQ Trial Snapshot
- A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. — Active Not Recruiting • Phase III • Oncology • NCT05984277.
- New drug volrustomig plus chemotherapy compared with pembrolizumab plus chemotherapy for advanced lung cancer with low PD-L1 levels.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 < 50%. Conditions: Metastatic Non-small Cell Lung Cancer Interventions: Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed Lead Sponsor: AstraZeneca Planned Enrollment: 895 participants